Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren Lasko, Kenneth D. Bromberg, Debra Montgomery et al.|Nature|2017Cited by 853
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Erwin R. Boghaert et al.|Molecular Cancer Therapeutics|2018Cited by 52